View
215
Download
0
Tags:
Embed Size (px)
DESCRIPTION
NIH Programs for NIH Programs for T l i lR h T l i lR h Translational Research Translational Research U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health
Citation preview
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health
NIH Programs for NIH Programs for T l i l R hT l i l R hTranslational ResearchTranslational Research
Stephanie Fertig, MBA (NINDS)T dd H i PhD (NCI)Todd Haim, PhD (NCI)
Kurt Marek, PhD (NHLBI)Jerry Wujek, PhD (NEI)
John McKew, PhD (NCATS)John McKew, PhD (NCATS)
Phase IIB ProgramsPhase IIB ProgramsPhase IIB ProgramsPhase IIB Programs
• Competing Renewal Phase IIB or Bridges Award• Competing Renewal, Phase IIB or Bridges Award• General Omnibus: NIA, NIAAA, NIAID, NICHD, NIDA,
NIDCD NIDDK NEI NIGMS NIMH NCATS ORIPNIDCD, NIDDK, NEI, NIGMS, NIMH, NCATS, ORIPo Some are focused on projects requiring FDA approvalo Specific IC research topics sections (omnibus) have
i t /i t tirequirements/instructions
• Specific Announcements: NCI, NHLBI, NINDSo Application includes a fundraising plano Application includes a fundraising plano Strongly Encourage Matching Funds
Contact Program Before Applying
SBIR Technology Transfer (SBIRSBIR Technology Transfer (SBIR‐‐TT)TT)• Transfer technology out of the NIH intramural research
labs into the private sectorP j t t l th f NIH i t l t h l• Projects must rely on the use of NIH intramural technology
• Investigator Initiated (Grants): NINDS, NHLBI, NEIApplication assignment follows extramural receipt and referral guidelineso Application assignment follows extramural receipt and referral guidelines
o NINDS and NEI: Technologies from any NIH intramural labo NHLBI: Technologies from any NHLBI intramural lab
• Request for Proposals (Contracts): NCI, NHLBI• Licensing Agreements:
o Granted a royalty-free, non-exclusive internal research-use if awardedo Can apply for an exclusive license agreement
Contract ResourcesContract ResourcesContract ResourcesContract Resources• Offer access to services instead of grant money
Examples:Examples:o cGMP Manufacturingo Pharmacokinetic/ADME Studieso Pharmacology/Toxicology Studieso Pharmacology/Toxicology Studieso Regulatory Supporto Clinical Supply Manufacturingo and many others…o and many others…
• Submission:o May or may not go through grants.gov
Not a standard grant applicationo Not a standard grant application• Review process:
o Not a standard review processo Varies from program to program
Contact Program Before ApplyingContact Program Before Applying
Translational Programs at NIMHTranslational Programs at NIMHggDrug Discovery/Development Programs:• SBIR Program:g
o Complex Technologies and Therapeutics Development for Mental Health (PA-11-133) o Early Stage Clinical Trials (NOT-MH-015)
• Other Programs open to Small Business:o National Cooperative Drug Discovery/ Development Groups (NCDDG) for the
Treatment of Mental Disorders, Drug or Alcohol Addiction (PAR-11-206/PAR-11-207)o Drug Discovery for Nervous System Disorders (PAR-10-001/PAR-10-002)o Novel NeuroAIDS Therapeutics (PAR-10-216)p ( )o Innovative Pilot Studies of Novel Mechanism of Action Compounds for Treating
Psychiatric Disorders (PAR-11-316)
Resources:Resources:• NIMH Psychoactive Drug Screening
Program: http://pdsp.med.unc.edu/indexR.html• Toxicological Evaluation of Novel Ligandsg g
Program: http://www.sri.com/biosciences/nimh/• NIMH Chemical Synthesis and Drug Supply Program http://nimh-
repository.rti.org/• NIMH Genetics Repository: https://www nimhgenetics org/• NIMH Genetics Repository: https://www.nimhgenetics.org/
Neurotherapeutics Discovery Programsp y gAt NINDS
Phase I/IITrials
Target ID Assay Screening Hit to LeadProof
of Pre-clinicalSafety
LeadO ti i ti Trials
ConceptSafetyOptimization
NIH Blueprint Neurotherapeutics Network (BPN)
SBIR/STTR Clinical
Translational Cooperative
NIH Small Business Program: General SBIR & STTR
Clinical Trials
Cooperative Agreement
SBIR/STTR Competing Renewal (Phase IIB)(Phase IIB)
Phase I/IITrials
Hit to LeadProof
ofConcept
Pre-clinicalSafety
LeadOptimization
Blueprint Blueprint NeurotherapeuticsNeurotherapeutics Grand ChallengeGrand Challenge
ConceptyOptimization
pp pp gg• “Virtual Pharma” structure
o Industry-standard servicesLead Development Team
o Industry standard serviceso Industry-seasoned consultantso Funding for biology
Principal InvestigatorIndustry-seasoned consultants
NIH staff
• PI retains control of IP• Entry Requirements:U01s NIH Contracts
o Strong biological rationaleo Robust assay for SAR, biological
validationW ll lid t d hit d
Bioactivity/EfficacyStudies
MedicinalChemistry
DataManagement
GMP S l U o Well-validated hit compound
RFA-NS-13-003~$125 K direct/year
PK/Tox
FormulationDevelopment
GMP Scale‐Up Synthesis
Phase IClinical Trials Due Oct 8th
Up to $10 M value per project, in total
Development Clinical Trials
NINDS Cooperative Program inNINDS Cooperative Program inNINDS Cooperative Program in NINDS Cooperative Program in Translational ResearchTranslational Research
Pre-clinicalSafety
LeadOptimization
• Pre-clinical development and testing of new therapies No mechanistic clinical or screening projectsNo mechanistic, clinical, or screening projects
• Goal: IND/IDE submission by the end of the project• Milestone driven cooperative agreement program for• Milestone-driven cooperative agreement program for
small business (U44) and academics, etc. (U01)• 3-5 years larger budget• 3-5 years, larger budget• Reviewed by therapy development experts• Significant staff involvement• Significant staff involvement • Contact Program Before Applying
PAR-11-296/PAR-11-294
NINDS E l t Cli i l T i lNINDS E l t Cli i l T i lNINDS Exploratory Clinical TrialsNINDS Exploratory Clinical Trialsfor Small Businessfor Small Business
Phase I/IITrials
• NINDS accepts Phase I/II Clinical Trials through specific program announcementsprogram announcements
• Phase III Clinical Trials are not accepted through the SBIR/STTR programSBIR/STTR program
• Evaluation of drugs, biologics, devices, or diagnostics as well as surgical, behavioral or rehabilitation therapiesg , p
• 3-5 years of funding, larger budget• Application includes clinical protocol, study organization and pp p , y g
administration section, data and safety monitoring plan
PAR 12 0 2/PAR 12 0 3PAR-12-072/PAR-12-073
NINDS SBIR/STTRNINDS SBIR/STTRNINDS SBIR/STTR NINDS SBIR/STTR Competing RenewalCompeting Renewal
Phase I/IITrials
Pre-clinicalSafety
LeadOptimization
NIH S ll B i P Pri ate In estmentSBIR/STTRValley of DeathNIH Small Business Program: General SBIR & STTR
Private InvestmentStrategic Partner
SBIR/STTR Competing Renewal
Specific announcements: / C f•PAR-12-074/PAR-12-075: Pre-Clinical Research for FDA Approval
•PAR-12-076/PAR-12-077: Phase I/II Clinical Trials
Strongly Encourage Matching Funds
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health
NCI Programs for NCI Programs for T l i l R hT l i l R hTranslational ResearchTranslational Researchhtt // bihttp://sbir.cancer.gov
Todd Haim, PhD Program Manager
NCI SBIR Development CenterNCI SBIR Development Center
NCI SBIR Development CenterNCI SBIR Development CenterppMichael Weingarten, MA (Director)Previous• NASA – Program Manager, NASA Technology Commercialization Program
Andrew J. Kurtz, PhD (Branch Chief)Previous• NIH AAAS Science & Technology Policy FellowCommercialization Program
Greg Evans, PhD (Branch Chief)Previous• NHLBI/NIH – Program Director, Translational and Multicenter Clinical Research in Hemoglobinopathies
• NIH – AAAS Science & Technology Policy Fellow• Cedra Corporation – Research Associate, Bio-
Analytical Assays and Pharmacokinetics Analysis
Jian Lou, PhD (Program Director)PreviousMulticenter Clinical Research in Hemoglobinopathies
• NHGRI/NIH – Senior Staff FellowPrevious• Johnson & Johnson – Research Scientist, Target
Validation & Biomarker Development• Lumicyte, Inc. – Director, Molecular Biology Systems Analysis
Patti Weber, DrPH (Program Director)Previous• International Heart Institute of Montana –
Deepa Narayanan, MS (Program Director)Previous
• International Heart Institute of Montana –Tissue Engineering and Surgical Research
• Ribi ImmunoChem Research, Inc. – Team Leader, Cardiovascular Pharmacology
Todd Haim, PhD (Program Manager)Previous• National Academy of Sciences – Christine Mirzayan
Science and Technology Policy Fellow• Pfizer Research Laboratories – Postdoctoral Fellow, C di P h i & M b li Di dPrevious
• Naviscan PET Systems, Inc., Director, Clinical Data Management (Oncology Imaging & Clinical Trials)
• Fox Chase Cancer Center, Scientific Associate(Molecular Imaging Lab)
Cardiac Pathogenesis & Metabolic Disorders
Amir Rahbar, PhD, MBA (Program Director)Previous• NCI– Program Director, Center for Strategic Scientific Initiatives
• BioInformatics, LLC – Senior Science Market Analyst• Naval Research Laboratory – Research Scientist
Jennifer Shieh, PhD (AAAS Science & Technology Policy Fellow)P i
Catherine Langston, MA (Program Analyst)
Julienne Willis (Program Specialist)Previous• National Academy of Sciences – Christine MirzayanScience and Technology Policy Fellow
• Syapse, Inc. – Biology Associate
NCI SBIR: Translational ResearchNCI SBIR: Translational Research
• Targeted Solicitations
• NCI Bridge Awardg
• NCI Investor Forum
Targeted SolicitationsTargeted Solicitationshttp://sbir cancer gov/funding/find funding asphttp://sbir cancer gov/funding/find funding asphttp://sbir.cancer.gov/funding/find_funding.asphttp://sbir.cancer.gov/funding/find_funding.asp
NCI SBIR C t t• NCI SBIR Contracts: http://sbir.cancer.gov/funding/contracts/o Released in August: Due around November (one submission date)o Approximately 25% of the funding portfolioo Topics are ripe for commercialization (e.g. Companion Diagnostics)o Tech Transfer: Soliciting proposals for development of specific NCI technologieso Conference Session: “The Ins and Outs of NIH SBIR Contracts”– Today at 3PMy
• RFAs and PAs: http://sbir cancer gov/funding/grants/• RFAs and PAs: http://sbir.cancer.gov/funding/grants/o Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnologyo Image Guided Interventions : Focus is on integration of component technologieso SBIR Innovative Molecular Analysis Technologies (IMAT): Commercial Feasibility
• http://innovation.cancer.gov/o More coming soon
NCI SBIR Bridge AwardNCI SBIR Bridge AwardPhase IIICOMMERCIALIZATION
Phase IIDEVELOPMENT
Phase IFEASIBILITY
NCI SBIR Phase II Bridge AwardCROSSING THE VALLEY OF DEATH
• NCI gives competitive preference and funding priority to applicants that raise substantial third-party funds (i e ≥ 1:1 match)that raise substantial third-party funds (i.e., ≥ 1:1 match)
• Broad Eligibilityo Current Phase II awards & and those that ended within the last 2 yearso Current Phase II awards & and those that ended within the last 2 yearso Cancer-related Phase II projects initially funded by other NIH institutes
• > 75% of NCI SBIR Phase II projects fit the scope of the awardo Cancer Therapeuticso Cancer Imaging Technologies, Interventional Devices & In Vivo Diagnosticso In Vitro and Ex Vivo Cancer Diagnostics and Prognostics
• Special Review to Evaluate Technical and Commercial Meritso Preferred Types of Funds: Cash, liquid assets, convertible debt
• 12 Awards to Date; > 2:1 Leverage
NCI SBIR Investor Forum NCI SBIR Investor Forum
Exclusive opportunity for NCI SBIR Awardees to i h h i h l i 100 i lpitch their technologies to > 100 venture capital or
strategic partner representatives (i.e. big pharma)http://sbir.cancer.gov/investorforum/
• The 2012 Forum was the 3rd NCI SBIR Investor Forumo Over 150 meetings occurred between SBIR awardees and Investors
• ~ 15 NCI SBIR Awardees are chosen to present at each evento External Reviewers included representatives from venture capital firms, big pharma, and large
device companies
• Each presenting company is mentored by an investment/industry• Each presenting company is mentored by an investment/industry professional
Th N b 2010 F h t l d ti• The November 2010 Forum has proven extremely productiveo 6 out of the 14 presenting companies have closed deals with total value > $230 Million
NCI Contract ResourcesNCI Contract Resources• NCI Experimental Therapeutics (NExT)
o Assists clinical translation of novel therapeutic interventions – anticancer drugs (small molecules, biologics) and imaging agents
o Provides access to preclinical drug discovery and clinical development resources o The next submission deadlines are June 15 and October 15 o http://next.cancer.gov.
• NCI PREVENT Preclinical Drug Development ProgramNCI PREVENT Preclinical Drug Development Programo Pipeline to bring new cancer-preventing interventions and biomarkers through preclinical
development towards clinical trialso Flexible entry-point system to optimize and test an agent with the goal of filing an INDo http://prevention.cancer.gov/programs-resources/programs/preventp p g p g p g po For clinical development resources, companies should apply to the Consortia for Early Phase
Prevention Trials: http://prevention.cancer.gov/clinicaltrials/management/consortia
• NCI Clinical Assay Development Program (CADP)NCI Clinical Assay Development Program (CADP)o Provides access to tissue and laboratory resources for analytical and clinical validation of assayso Eligible applicants must have a working prototype assay with a clearly defined clinical useo The next submission deadlines are June 15 and October 15o http://cadp cancer govo http://cadp.cancer.gov.
• For additional resources including biospecimen resources, chemicals repository and cancer imaging archives, please visit htt // bi / / t /http://sbir.cancer.gov/resource/grantees/